Abbott Laboratories (NYSE:ABT) Stock Sale Reported by Rep. Pete Sessions

Representative Pete Sessions (Republican-Texas) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on October 27th, the Representative disclosed that they had sold between $50,001 and $100,000 in Abbott Laboratories stock on October 2nd. The trade occurred in the Representative’s “TRUST ONE” account.

Representative Pete Sessions also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Walt Disney (NYSE:DIS) on 10/28/2026.
• Sold $15,001 – $50,000 in shares of Amazon.com (NASDAQ:AMZN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of McDonald’s (NYSE:MCD) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of Lowe’s Companies (NYSE:LOW) on 10/22/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 10/22/2026.
• Sold $1,001 – $15,000 in shares of Solstice Advanced Mat (NASDAQ:SOLS) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 10/21/2026.
• Sold $0 – $1,000 in shares of Resideo Technologies (NYSE:REZI) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 10/20/2026.
• Sold $15,001 – $50,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 10/15/2026.

Abbott Laboratories Trading Down 0.4%

Abbott Laboratories stock opened at $102.66 on Thursday. The firm has a market capitalization of $177.64 billion, a price-to-earnings ratio of 38.31, a P/E/G ratio of 1.82 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02. The firm has a 50 day moving average of $104.72 and a 200 day moving average of $102.26. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.42. The firm had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.30 earnings per share. As a group, research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s payout ratio is presently 94.03%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE bought a new stake in shares of Abbott Laboratories in the 2nd quarter valued at approximately $1,603,607,000. Legal & General Group Plc purchased a new stake in Abbott Laboratories during the 2nd quarter valued at $1,082,524,000. Flossbach Von Storch SE bought a new stake in Abbott Laboratories in the second quarter worth $902,938,000. Jupiter Topco LLC bought a new stake in Abbott Laboratories in the second quarter worth $732,788,000. Finally, BlackRock Inc. boosted its stake in Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after buying an additional 6,769,518 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on ABT. Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price for the company in a research note on Thursday, August 13th. Robert W. Baird boosted their price target on shares of Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a research note on Thursday, October 22nd. TD Cowen dropped their price objective on shares of Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating for the company in a report on Thursday, October 22nd. Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and raised their price objective for the company from $119.00 to $127.00 in a research report on Friday, October 2nd. Finally, Wall Street Zen raised Abbott Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, October 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.32.

About Representative Sessions

Pete Sessions (Republican Party) is a member of the U.S. House, representing Texas’ 17th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Sessions (Republican Party) ran for re-election to the U.S. House to represent Texas’ 17th Congressional District. He won in the general election on November 5, 2024.

On October 20, 2023, Sessions announced he was running to replace Kevin McCarthy (R) as speaker of the U.S. House in the 118th Congress. Sessions lost the first round of nomination voting on October 24, 2023.

Pete Sessions was born and lives in Waco, Texas. Sessions earned a B.S. from Southwestern University in 1978. Sessions’ career experience includes working as an executive with AT&T.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.